Health Canada approves Lipocine partner Verity's TLANDO oral testosterone; Canadian launch planned by end of 2026

Lipocine Inc.

Health Canada approved TLANDO (testosterone undecanoate) capsules for testosterone replacement therapy in adult males with hypogonadism; fixed dose, no titration required.
Licensing partner Verity Pharmaceuticals holds exclusive North American commercial rights and is planning launch and commercialization in Canada by the end of 2026.
Canada's TRT market writes more than 700,000 prescriptions annually; roughly 50% of that patient population is covered through private insurance.
Lipocine granted Verity exclusive US and Canada rights under a January 2024 license; Verity is responsible for regulatory, commercialization and franchise development.
No financial terms, royalty rates or milestone amounts from the Verity agreement were disclosed; TLANDO is already FDA-approved in the US for hypogonadism.

This headline and bullets were generated automatically by deepseek-v4.1-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.